Mohamed ABOUBAKR, Mossad ELSAYED, Ashraf ELKOMY

Effect of ceftriaxone on blood pressure, respiration and its analgesic and antipyretic activities

Amaç: Araştırmanın amacı seftriaksonun köpeklerde kan basıncı ve solunuma etkisini aratırmaktır. Ayrıca seftriaksonun fare ve ratlarda anajezik ve antipretik etkiliği de araştırıldı. Gereç ve Yöntem: Faklı dozlarda seftriaksonun (26.66, 53.33, 106.66 mg/kg, IV) anestezi altındaki köpeklerde kan basıncı ve solunuma etkisi belirlendi. İki farklı dozda seftriaksonun ise fare ve ratlarda anajezik ve antipretik etkinliği belirlendi. Bulgular: Seftriaksonun anestezi altındaki köpeklerin kan basıncı ve solunuma etkisinin olmadığı belirlendi. Ancak seftriaksonun (260 ve 520 mg/kg) dört saat süresince analjezik ve 180 ile 360 mg/kg dozlarda sırasıyla 2.5 ve 1.5 saat süresince antipretik etkinlik gösterdiği belirlendi. Öneri: Seftriakson bakterial ve ateşli enfeksiyonlarda antibakteriyel, analjezik ve antipretik etkinliğinden dolayı tercih edilebilir.

Sefriaksonun kan basıncı ile solunuma etkisi ve anajejik ile antipretik aktiviteleri

Aim: The aim of this study was to determine the effect of ceftriaxone on blood pressure and respiration in dog. In addition, analgesic and antipyretic activities of ceftriaxone were investigated in mice and rats. Materials and Methods: Effect of different doses of ceftriaxone (26.66, 53.33, 106.66 mg/kg, IV) on blood pressure and respiration rate were determined in anesthetized dogs. Analgesic and antipyretic activities of two different doses of ceftriaxone were investigated in mice and rats, respectively. Results: Ceftriaxone had no effect on blood pressure and rate of respiration in anesthetized dogs. However, ceftriaxone (260 and 520 mg/kg) had a significant analgesic effect for four hours and had a significant antipyretic effect at 2.5 and 1.5 hours at doses of 180 and 360 mg/kg, respectively. Conclusion: Ceftriaxone is preferable in bacterial infections or feverish conditions owing to its antibacterial, antipyretic and analgesic activities.

PDF

___

Alpermann H, 1972. British uber pharmacologische untersuchurgen min fenbendazol. Abteilung fur Pharmacologie, 863, 1-9.
Bourget P, Fernandez H, Quinquis V, Delouis C, 1993. Pharmacokinetics and protein binding of ceftriaxone during pregnancy. Antimicrob Agents Chemother, 37, 5437- 5459.
Eddy H, 1982. Cited in selected topics in experimental pharmacology by Sheath Dadcar and Kamat (1972). The Kothari book Depot, Parel, Bombany.
El-Sayed M, El-Komy A, Aboubakr M, 2011. Effect of ceftriaxone on isolated smooth, cardiac muscles and neuromuscular junctions. IJAVMS, 5, 138-151.
El-Sayed MG, Hassanin MR, Hafez MH, El-Komy AA, Mohamed A, 1997. Some pharmacodynamic and biochemical aspects of cefamandole. Dtsch Tierarztl Wochenschr, 104, 481-487.
Goto A, Amano M, Sakai A, Hara M, Takahashi N, 1992. General pharmacology of cefepime. Jpn J Antibiot, 45, 661- 680.
Harold CN, 1985. Relation of structural properties of beta lactam antibiotics to antibacterial activity. Am J Med, 79, 2–13.
Hasegawa Y, Muto N, Morita M, 1979. General pharmacology of cefadroxil. Jpn J Antibiot, 32, 1356-1371.
Hirai S, Kodama T, Hiraiwa T, Abe N, Arai H, Ono S, Omori M, Nakada Y, Hashiba K, Tanada K, 1986. General pharmacology of T-2588, a new oral cephem antibiotic. Jpn J Antibiot, 39, 958-978.
Honda F, Ono T, Itoh N, Mori J, Ohtsuka M, Kamitani T, 1980. General pharmacology of ceftizoxime sodium. Arzneimittelforschung, 30, 1680-1687.
Jackson DE, 1939. Experimental pharmacology and materia media, Hynry, Kympton, 1st edition, London, UK, pp. 65.
Jenien PA, Jageneou A, 1957. New series of potent analgesic, Part 1, chemical structure and pharmacological activity. J Pharma Pharmacol, 9, 381.
Kurebe M, Asaoka H, Yamaki Y, Sugiyama S, Shibasaki Y, Nishimori T, Kobayashi F, 1984. Pharmacological studies on new cephamycin, MT-141. (1) Its effect on central nervous system, respiration and cardiovascular system. Jpn J Antibiot, 37, 1428-1439.
Neu HC, Merpol NJ, Fu KP, 1981. Antibacterial activity of ceftriaxone, beta-lactamase-stable cephalosporin. Antimicrob Agents Chemother, 19, 414–423.
Rawls SM, Tallarida R, Robinson W, Amin M, 2007. The beta- lactam antibiotic, ceftriaxone, attenuates morphineevoked hyperthermia in rats. Br J Pharmacol, 151, 1095- 1102.
Rawls SM, Zielinski M, Patel H, Sacavage S, Baron DA, Patel D, 2010. Beta-lactam antibiotic reduces morphine analgesic tolerance in rats through GLT-1 transporter activation. Drug Alcohol Depend, 107, 261-263.
Shetler T, Bendele A, Buening M, Clemens J, Colbert W, Deldar A, Helton D, McGrath J, Shannon H, Turk J, 1993.
General pharmacology of loracarbef in animals. Arzneimittelforschung, 43, 60-70.
Takai A, Hirai S, Watanabe I, Hiraiwa T, Abe N, Arai H, Omori M, Tanada K, Senda N, Hashiba K, Matsukura K, Takata K, Okami H, 1982. General pharmacology of T-1982, a new cephamycin antibiotic. Jpn J Antibiot, 35, 2139-2154.
Takai A, Hirai S, Watanabe I, Hiraiwa T, Abe N, Omori M, Muroda T, Nakajima S, Nakada Y, Tanada K, Senda N, Tanaka K, Makino H, 1980. General pharmacology of cefoperazone, a new cephalosporin antibiotic. Jpn J Antibiot, 33, 994-1018.
Zhou HH, Chan YP, Arnold K, Sun M, 1985. Single dose pharmacokinetics of ceftriaxone in healthy Chinese adults. Antimicrob Agents Chemother, 27, 192-196.